<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03346187</url>
  </required_header>
  <id_info>
    <org_study_id>146BE16007</org_study_id>
    <nct_id>NCT03346187</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Compare Safety and Pharmacokinetic Characteristics of CKD-337</brief_title>
  <official_title>A Randomized, Open-label, Single Oral Dose, 2-way Crossover Clinical Trial to Compare Safety and Pharmacokinetic Characteristics of CKD-337 in Healthy Male Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chong Kun Dang Pharmaceutical</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chong Kun Dang Pharmaceutical</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A randomized, open-label, single oral dose, 2-way crossover clinical trial to compare safety&#xD;
      and pharmacokinetic characteristics of CKD-337 in healthy male volunteers&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized, open-label, single oral dose, 2-way crossover clinical trial to&#xD;
      compare safety and pharmacokinetics of CKD-337 in healthy male volunteers.&#xD;
&#xD;
      Subjects will receive either a single oral dose of the test formulation(CKD-337) or a oral&#xD;
      dose of the reference formulation(Atorvastatin Calcium Trihydrate+Fenofibrate).&#xD;
&#xD;
      Each treatment period was separated by a washout period of at least 7 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 19, 2017</start_date>
  <completion_date type="Actual">June 13, 2017</completion_date>
  <primary_completion_date type="Actual">May 31, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Atorvastatin AUCt(Area under the plasma drug concentration-time curve)</measure>
    <time_frame>Predose(0hr), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48hr after drug administration]</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Atorvastatin Cmax(Maximum plasma concentration)</measure>
    <time_frame>Predose(0hr), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48hr after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Fenofibric acid AUCt</measure>
    <time_frame>Predose(0hr), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96hr after drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Fenofibric acid Cmax</measure>
    <time_frame>Predose(0hr), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96hr after drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Atorvastatin AUCinf(Area under plasma concentration-time curve from time point of administration to infinite)</measure>
    <time_frame>Predose(0hr), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48hr after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atorvastatin Tmax(Time taken to reach the maximum concentration)</measure>
    <time_frame>Predose(0hr), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48hr after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atorvastatin t1/2(Terminal half-life, Time for Cmax to drop in half)</measure>
    <time_frame>Predose(0hr), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48hr after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atorvastatin CL/F(Apparent total body clearance after extravascular administration, calculated as Dose/AUC)</measure>
    <time_frame>Predose(0hr), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48hr after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Atorvastatin Vd/F(Apparent volume of distribution/Bioavailability)</measure>
    <time_frame>Predose(0hr), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48hr after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fenofibric acid AUCinf</measure>
    <time_frame>Predose(0hr), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96hr after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fenofibric acid Tmax</measure>
    <time_frame>Predose(0hr), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96hr after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fenofibric acid t1/2</measure>
    <time_frame>Predose(0hr), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96hr after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fenofibric acid CL/F</measure>
    <time_frame>Predose(0hr), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96hr after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fenofibric acid Vd/F</measure>
    <time_frame>Predose(0hr), 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48, 72, 96hr after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-hydroxy atorvastatin AUCt</measure>
    <time_frame>Predose(0hr), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48hr after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-hydroxy atorvastatin Cmax</measure>
    <time_frame>Predose(0hr), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48hr after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-hydroxy atorvastatin AUCinf</measure>
    <time_frame>Predose(0hr), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48hr after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-hydroxy atorvastatin Tmax</measure>
    <time_frame>Predose(0hr), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48hr after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-hydroxy atorvastatin t1/2</measure>
    <time_frame>Predose(0hr), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48hr after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-hydroxy atorvastatin CL/F</measure>
    <time_frame>Predose(0hr), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48hr after drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>2-hydroxy atorvastatin Vd/F</measure>
    <time_frame>Predose(0hr), 0.25, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48hr after drug administration</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Dyslipidemias</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: Active Comparator(Atorvastatin Calcium Trihydrate+Fenofibrate), 2 tablets administered under fed conditions.&#xD;
Period 2: test drug(CKD-337 : Atorvastatin Calcium Trihydrate + Fenofibrate), 1 capsule administered under fed conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period 1: test drug(CKD-337 : Atorvastatin Calcium Trihydrate + Fenofibrate), 1 capsule administered under fed conditions.&#xD;
Period 2: Active Comparator(Atorvastatin Calcium Trihydrate+Fenofibrate), 2 tablets administered under fed conditions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Active Comparator(Atorvastatin Calcium Trihydrate+Fenofibrate)</intervention_name>
    <description>Lipitor(Atorvastatin Calcium Trihydrate 20mg/tablet) + Lipidil supra(Fenofibrate 160mg/tablet)</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Test drug(CKD-337)</intervention_name>
    <description>CKD-337(Atorvastatin calcium trihydrate 20mg+choline fenofibrate 178.8mg/capsule)</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  Inclusion Criteria:&#xD;
&#xD;
               1. Healthy male older than 19 years and under 45 years at the time of screening&#xD;
&#xD;
               2. BMI 17.5~30.5 kg/m² and body weight more than 55kg&#xD;
&#xD;
                    -  BMI = Weight(kg)/{Height(m)}²&#xD;
&#xD;
               3. Subject who is no chronic disease, no symptoms or pathological findings&#xD;
&#xD;
               4. Suitable subject who is determined by laboratory tests(hematology test, blood&#xD;
                  chemistry, urinalysis test etc.), Vital Sign, ECG test at the time of screening&#xD;
&#xD;
               5. Subject who fully understand the clinical trials after in-depth explanation,&#xD;
                  decide to join the clinical trials and sign on an inform consent from willing&#xD;
&#xD;
          -  Exclusion Criteria:&#xD;
&#xD;
               1. Subject who has a clinically significant disease such as hepatic, kidneys,&#xD;
                  neurological, respiratory, endocrine, hemato-oncology, urinary, cardiovascular,&#xD;
                  musculoskeletal or psychiatric diseases and who has a following history&#xD;
&#xD;
                    -  Gallbladder disease including cholelithiasis, severe hepatic impairment&#xD;
&#xD;
                    -  Acute/chronic pancreatitis due to hypertriglyceridemia&#xD;
&#xD;
                    -  Pulmonary embolism or interstitial lung disease&#xD;
&#xD;
                    -  Genetic problems such as galactose intolerance, Lapp lactase deficiency,&#xD;
                       glucose-galactose malabsorption&#xD;
&#xD;
                    -  Hypoalbuminemia&#xD;
&#xD;
                    -  Alcoholics&#xD;
&#xD;
                    -  Predisposition to rhabdomyolysis&#xD;
&#xD;
               2. Subject who has a history of gastrointestinal disease or gastrointestinal surgery&#xD;
                  which can affect drug absorption&#xD;
&#xD;
               3. Subject who has hypersensitivity to the drug composition containing choline&#xD;
                  fenofibrate, fenofibrate or atorvastatin, and other drug(aspirin, fenofibrate&#xD;
                  series, antibiotic and so on)&#xD;
&#xD;
               4. The following clinical significant findings in the EKG at the time of screening&#xD;
&#xD;
                    -  QTc(Q-T interval corrected for heart rate) &gt; 450ms&#xD;
&#xD;
                    -  PR interval(The interval between the beginning of the P wave and the&#xD;
                       beginning of the QRS complex in ECG) &gt; 200msec&#xD;
&#xD;
                    -  QRS duration(The duration of the Q,R and S wave in ECG) &gt; 120msec&#xD;
&#xD;
               5. The following results in the clinical laboratory tests&#xD;
&#xD;
                    -  CPK(Creatinine Phospho-Kinase) &gt; 2 x upper limit of normal range&#xD;
&#xD;
                    -  Liver function test(AST; Aspartate Transaminase, ALT; Alanine Transaminase,&#xD;
                       ALP; Alkaline phosphatase, Total bilirubin, γ-GT) &gt; 2 x upper limit of&#xD;
                       normal range&#xD;
&#xD;
                    -  eGFR(Estimated Glomerular Filtration Rate) &lt; 60 mL/min/1.73m² Calculated by&#xD;
                       MDRD(Modification of Diet in Renal Disease)&#xD;
&#xD;
               6. Systolic blood pressure ≥ 160mmHg(millimeter of mercury) or ≤ 100mmHg(millimeter&#xD;
                  of mercury) , Diastolic blood pressure ≥ 95mmHg(millimeter of mercury) or ≤&#xD;
                  60mmHg(millimeter of mercury) at the time of screening&#xD;
&#xD;
               7. History of drug abuse or a positive reaction for drug abuse in the urine at the&#xD;
                  time of screening&#xD;
&#xD;
               8. Taking medicines that are known to significantly induce or inhibit drug&#xD;
                  metabolizing enzymes, including barbiturates, within 30 days of the first dosing&#xD;
&#xD;
               9. Those who experience photoallergy or phototoxicity during treatment with fibrates&#xD;
                  or ketoprofen&#xD;
&#xD;
              10. Taking ETC(Ethical Drug), oriental medicine within 2 weeks and&#xD;
                  OTC(Over-the-counter Drug), vitamin within 10 days before the first dosing&#xD;
&#xD;
              11. Taking the medication involved in other clinical trials within 3 months before&#xD;
                  the first dosing&#xD;
&#xD;
              12. Whole blood donation with 2 months, component blood donation or blood transfusion&#xD;
                  within 1 month before the first dosing&#xD;
&#xD;
              13. Alcohol &gt; 21 units/week (1unit=10g of pure alcohol), continuously within 6 month&#xD;
                  before the first dosing or Who can not stop drinking alcohol during the clinical&#xD;
                  trial&#xD;
&#xD;
              14. Smoker(&gt; 10 cigarettes/day) for the last 3 months or who can not stop smoking&#xD;
                  during the clinical trial&#xD;
&#xD;
              15. Consumption of food containing grapefruit within 48 hours before first dosing and&#xD;
                  who can not stop consumption it until EOS(End of study)&#xD;
&#xD;
              16. Consumption of food containing caffeine(e.g. coffee, green tea etc.) within 24&#xD;
                  hours before first dosing and who can not stop consumption it until discharge&#xD;
&#xD;
              17. Not using a reliable contraception or planning a pregnancy during the clinical&#xD;
                  trial&#xD;
&#xD;
              18. Unsuitable Conditions including laboratory result by investigator's judgement&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dong-A University Hospital</name>
      <address>
        <city>Busan</city>
        <state>Seo-gu</state>
        <zip>602-812</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <study_first_submitted>November 15, 2017</study_first_submitted>
  <study_first_submitted_qc>November 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2017</study_first_posted>
  <last_update_submitted>December 17, 2017</last_update_submitted>
  <last_update_submitted_qc>December 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
    <mesh_term>Fenofibrate</mesh_term>
    <mesh_term>Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

